

DAFTAR PUSTAKA

- Alshiekh Nasany, R. and de la Fuente, M.I. (2023) ‘Therapies for IDH-Mutant Gliomas’, *Current Neurology and Neuroscience Reports*, 23(5), pp. 225–233. Available at: <https://doi.org/10.1007/s11910-023-01265-3>.
- Ardhini, R. and Tugasworo, D. (2019) ‘Epidemiology of primary brain tumors in dr. Kariadi Hospital Semarang in 2015-2018’, *E3S Web of Conferences*, 125, p. 16004. Available at: <https://doi.org/10.1051/e3sconf/201912516004>.
- Balana, C. *et al.* (2022) ‘Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics’, *Frontiers in Neurology*, 13. Available at: <https://doi.org/10.3389/fneur.2022.865171>.
- Berger, T.R. *et al.* (2022) ‘World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas’, *JAMA Oncology*, 8(10), pp. 1493–1501. Available at: <https://doi.org/10.1001/jamaoncol.2022.2844>.
- Biswas, A. *et al.* (2022) ‘Features of Visually Accessible Rembrandt Images: Interrater Reliability in Pediatric Brain Tumors’, *American Journal of Neuroradiology*, 43(2), pp. 304–308. Available at: <https://doi.org/10.3174/ajnr.A7399>.
- Cao, M. *et al.* (2021) ‘Qualitative and Quantitative MRI Analysis in IDH1 Genotype Prediction of Lower-Grade Gliomas: A Machine Learning Approach’, *BioMed Research International*. Edited by Z. Zhou, 2021, p. 1235314. Available at: <https://doi.org/10.1155/2021/1235314>.
- Carrano, A. *et al.* (2021) ‘Sex-Specific Differences in Glioblastoma’, *Cells*, 10(7), p. 1783. Available at: <https://doi.org/10.3390/cells10071783>.
- Gemini, L. *et al.* (2023) ‘Vasari Scoring System in Discerning between Different Degrees of Glioma and IDH Status Prediction: A Possible Machine Learning Application?’, *Journal of Imaging*, 9(4), p. 75. Available at: <https://doi.org/10.3390/jimaging9040075>.
- Grochans, S. *et al.* (2022) ‘Epidemiology of Glioblastoma Multiforme–Literature Review’, *Cancers (Basel)*, 14(10), p. 2412. Available at: <https://doi.org/10.3390/cancers14102412>.
- Grover, V.P.B. *et al.* (2015) ‘Magnetic Resonance Imaging: Principles and Techniques: Lessons for Clinicians’, *Journal of Clinical and Experimental Hepatology*, 5(3), pp. 246–255. Available at: <https://doi.org/10.1016/j.jceh.2015.08.001>.

- Han, Y. *et al.* (2018) ‘Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis’, *BMC Cancer*, 18(1), p. 215. Available at: <https://doi.org/10.1186/s12885-018-4114-2>.
- Hanif, F. *et al.* (2017) ‘Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment’, *Asian Pacific Journal of Cancer Prevention*, 18(1), pp. 3–9.
- Haque, W. *et al.* (2021) ‘Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas’, *Journal of Clinical Neuroscience*, 85, pp. 115–121. Available at: <https://doi.org/10.1016/j.jocn.2020.12.028>.
- Hofer, S. *et al.* (2014) ‘Molecular biology of high-grade gliomas: what should the clinician know?’, *Chinese Journal of Cancer*, 33(1), pp. 4–7. Available at: <https://doi.org/10.5732/cjc.013.10218>.
- Ijzerman-Korevaar, M. *et al.* (2018) ‘Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review’, *Journal of Neuro-Oncology*, 140(3), pp. 485–496. Available at: <https://doi.org/10.1007/s11060-018-03015-9>.
- Kayabolen, A., Yilmaz, E. and Bagci-Onder, T. (2021) ‘IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?’, *Biomedicines*, 9(7), p. 799. Available at: <https://doi.org/10.3390/biomedicines9070799>.
- Kim, Y.Z., Kim, C.-Y. and Lim, D.H. (2022) ‘The Overview of Practical Guidelines for Gliomas by KSN0, NCCN, and EANO’, *Brain Tumor Research and Treatment*, 10(2), pp. 83–93. Available at: <https://doi.org/10.14791/btrt.2022.0001>.
- Leske, H. *et al.* (2023) ‘MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value’, *Acta Neuropathologica Communications*, 11(1), p. 139. Available at: <https://doi.org/10.1186/s40478-023-01622-w>.
- Leveille, E. and Taylor, J. (2024) *Glioma, National Organization for Rare Disorders*.
- Lin, D. *et al.* (2021) ‘Trends in Intracranial Glioma Incidence and Mortality in the United States, 1975-2018’, *Frontiers in Oncology*, 11. Available at: <https://doi.org/10.3389/fonc.2021.748061>.
- Louis, D.N. *et al.* (2021) ‘The 2021 WHO Classification of Tumors of the Central Nervous System: a summary’, *Neuro-Oncology*, 23(8), pp. 1231–1251. Available at: <https://doi.org/10.1093/neuonc/noab106>.

- Malueka, R. *et al.* (2020) ‘Comparison of Polymerase Chain Reaction–Restriction Fragment Length Polymorphism, Immunohistochemistry, and DNA Sequencing for the Detection of IDH1 Mutations in Gliomas’, *Asian Pacific Journal of Cancer Prevention*, 21(11), pp. 3229–3234. Available at: <https://doi.org/10.31557/APJCP.2020.21.11.3229>.
- Malueka, R.G. *et al.* (2020) ‘Clinicopathological Features and Prognosis of Indonesian Patients with Gliomas with IDH Mutation: Insights into Its Significance in a Southeast Asian Population’, *Asian Pacific Journal of Cancer Prevention*, 21(8), pp. 2287–2295. Available at: <https://doi.org/10.31557/APJCP.2020.21.8.2287>.
- Malueka, R.G. *et al.* (2022) ‘Associations among smoking, IDH mutations, MGMT promoter methylation, and grading in glioma: a cross-sectional study’, *F1000Research*, 11, p. 473. Available at: <https://doi.org/10.12688/f1000research.110726.1>.
- Mesfin, F.B., Karsonovich, T. and Al-Dhahir, M.A. (2024) ‘Gliomas’, *StatPearls* [Preprint].
- Mughal, A.A. *et al.* (2018) ‘Patterns of Invasive Growth in Malignant Gliomas—The Hippocampus Emerges as an Invasion-Spared Brain Region’, *Neoplasia*, 20(7), pp. 643–656. Available at: <https://doi.org/10.1016/j.neo.2018.04.001>.
- Ostrom, Q.T. *et al.* (2014) ‘The epidemiology of glioma in adults: a “state of the science” review’, *Neuro-Oncology*, 16(7), pp. 896–913. Available at: <https://doi.org/10.1093/neuonc/nou087>.
- Ostrom, Q.T. *et al.* (2018) ‘Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014’, *JAMA Oncology*, 4(9), pp. 1254–1262. Available at: <https://doi.org/10.1001/jamaoncol.2018.1789>.
- Ostrom, Q.T. *et al.* (2019) ‘Risk factors for childhood and adult primary brain tumors’, *Neuro-Oncology*, 21(11), pp. 1357–1375. Available at: <https://doi.org/10.1093/neuonc/noz123>.
- Park, Y.W. *et al.* (2018) ‘Prediction of IDH1-Mutation and 1p/19q-Codeletion Status Using Preoperative MR Imaging Phenotypes in Lower Grade Gliomas’, *American Journal of Neuroradiology*, 39(1), pp. 37–42. Available at: <https://doi.org/10.3174/ajnr.A5421>.
- Pons-Escoda, A. *et al.* (2024) ‘Presurgical diagnosis of diffuse gliomas in adults: Post-WHO 2021 practical perspectives from radiologists in neuro-oncology units’, *Radiologia (English Edition)*, 66(3), pp. 260–277. Available at: <https://doi.org/10.1016/j.rxeng.2024.03.002>.

- Rafique, Z. *et al.* (2022) 'Diagnostic Accuracy of Magnetic Resonance Spectroscopy in Predicting the Grade of Glioma Keeping Histopathology as the Gold Standard', *Cureus*, 14(2). Available at: <https://doi.org/10.7759/cureus.22056>.
- Rajaratnam, V. *et al.* (2020) 'Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments', *Cancers (Basel)*, 12(4), p. 937. Available at: <https://doi.org/10.3390/cancers12040937>.
- Rivera, A.L. *et al.* (2010) 'MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma', *Neuro-Oncology*, 12(2), pp. 116–121. Available at: <https://doi.org/10.1093/neuonc/nop020>.
- Rodríguez-Camacho, A. *et al.* (2022) 'Glioblastoma Treatment: State-of-the-Art and Future Perspectives', *International Journal of Molecular Sciences*, 23(13), p. 7207. Available at: <https://doi.org/10.3390/ijms23137207>.
- Ruffle, J.K. *et al.* (2024) 'VASARI-auto: Equitable, efficient, and economical featurisation of glioma MRI', *NeuroImage: Clinical*, 44. Available at: <https://doi.org/10.1016/j.nicl.2024.103668>.
- Sahu, A. *et al.* (2022) 'Multiparametric Magnetic Resonance Imaging Correlates of Isocitrate Dehydrogenase Mutation in WHO high-Grade Astrocytomas', *Journal of Personalized Medicine*, 13(1), p. 72. Available at: <https://doi.org/10.3390/jpm13010072>.
- Sakata, S., Arai, K. and Kawamata, T. (2021) 'A subcutaneous mass due to a glioblastoma which invaded and destroyed the bone: A case report', *Interdisciplinary Neurosurgery*, 25, p. 101194. Available at: <https://doi.org/10.1016/j.inat.2021.101194>.
- Schramm, M.W.J. *et al.* (2023) 'Do animal models of brain tumors replicate human peritumoral edema? a systematic literature search', *Journal of Neuro-Oncology*, 161(3), pp. 451–467. Available at: <https://doi.org/10.1007/s11060-023-04246-1>.
- Setyawan, N.H. *et al.* (2024) 'Beyond invasive biopsies: using VASARI MRI features to predict grade and molecular parameters in gliomas', *Cancer Imaging*, 24(1), p. 3. Available at: <https://doi.org/10.1186/s40644-023-00638-8>.
- Singh, G. *et al.* (2021) 'Radiomics and radiogenomics in gliomas: a contemporary update', *British Journal of Cancer*, 125(5), pp. 641–657. Available at: <https://doi.org/10.1038/s41416-021-01387-w>.

- Smithuis, R. and Montanera, W. (2008) *Systematic Approach to Brain Tumors, Radiology Assistant*.
- So, J.-S., Kim, H. and Han, K.-S. (2021) 'Mechanisms of Invasion in Glioblastoma: Extracellular Matrix, Ca²⁺ Signaling, and Glutamate', *Frontiers in Cellular Neuroscience*, 15. Available at: <https://doi.org/10.3389/fncel.2021.663092>.
- Sun, X. *et al.* (2020) 'Radiomic prediction models for the level of Ki-67 and p53 in glioma', *Journal of International Medical Research*, 48(5). Available at: <https://doi.org/10.1177/0300060520914466>.
- Tan, A.C. *et al.* (2020) 'Management of glioblastoma: State of the art and future directions', *CA: A Cancer Journal for Clinicians*, 70(4), pp. 299–312. Available at: <https://doi.org/10.3322/caac.21613>.
- Theresia, E. *et al.* (2020) 'Association between Ki-67 Labeling index and Histopathological Grading of Glioma in Indonesian Population', *Asian Pacific Journal of Cancer Prevention*, 21(4), pp. 1063–1068. Available at: <https://doi.org/10.31557/APJCP.2020.21.4.1063>.
- Tian, M. *et al.* (2018) 'Impact of gender on the survival of patients with glioblastoma', *Bioscience Reports*, 38(6). Available at: <https://doi.org/10.1042/BSR20180752>.
- Wang, G.-M. *et al.* (2022) 'Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas', *Neuro-Oncology*, 24(2), pp. 302–310. Available at: <https://doi.org/10.1093/neuonc/noab199>.
- Xu, G. *et al.* (2021) 'Correlation between preoperative inflammatory markers, Ki-67 and the pathological grade of glioma', *Medicine*, 100(36), p. e26750. Available at: <https://doi.org/10.1097/MD.00000000000026750>.
- Xu, S. *et al.* (2020) 'Immunotherapy for glioma: Current management and future application', *Cancer Letters*, 476, pp. 1–12. Available at: <https://doi.org/10.1016/j.canlet.2020.02.002>.
- You, W. *et al.* (2023) 'The combination of radiomics features and VASARI standard to predict glioma grade', *Frontiers in Oncology*, 13. Available at: <https://doi.org/10.3389/fonc.2023.1083216>.
- Zhou, H. *et al.* (2017) 'MRI features predict survival and molecular markers in diffuse lower-grade gliomas', *Neuro-Oncology*, 19(6), pp. 862–870. Available at: <https://doi.org/10.1093/neuonc/now256>.